MONTREAL--(BUSINESS WIRE)--Ability Biologics (“Ability” or “the company”) announced the closing of its $12 million (US) financing round led by founding investor Amplitude Ventures. Amplitude is joined ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback